Chongxi Yu, Founder/CEO, Ph. D. in Bioorganic Chemistry from the State University of New Jersey, USA. He worked as a postdoctoral associate in University of Kentucky and then in University of Minnesota from June, 1995 to April, 1998. Afterwards, he took the post of R&D Manager in Chem-Impex International Inc. for more than 5 years. He is the first who put forward a new theory about drug absorption, and through years of effort, he has not only proved the correctness of the theory, but also established a new platform of transdermally delivering drugs according to it. With 22 international invention patents in hand, he is the inventor of the novel transdermal drug delivery technology.
Thomas A. Dahl, resposible for Operational Affairs, Ph.D. in Genetics and Biochemistry from the Johns Hopkins University, USA. He was an accomplished biotech/pharma executive with expertise in early stage ventures, including technical and market analysis of products and technologies, fundraising, business strategy and operationalization, development program strategy, clinical trial design and interpretation, and presentation to funding communities, analysts and pharma partners. He also took senior management positions, including President, CEO, and COO, in a number of emerging companies which had enjoyed the success of acquisition, partnership or becoming public entities through IPO or reverse merger.
Lina Xu, Co-Founder/Vice President, M.S. in Chemistry from Zhejiang University. She has 8 years of experience in drug research and development. with rich experience in new product development and project management, she mainly assists Dr. Yu with his work, responsible for new drug development and patent application as well as daily affairs management of the company.
Derek (Yuanchao) Zhang, resposible for Regulatory Affairs, Ph.D. in bioengineering and therapeutics from the University of California, San Francisco (UCSF), USA. He has 14 years of experience in drug research, development and regulatory approval, including 4 years of industrial experience at Pfizer and over 6 years of regulatory experience at the FDA. He was Senior Clinical Pharmacology Reviewer in the Office of Clinical Pharmacology, the Center for Drug Evaluation and Research, the Food and Drug Administration. He successfully reviewed numerous NDAs (including several NME NDAs and BLAs), NDA supplements, and IND submissions. He also contributed to several guidance document development and revision.
Gustavo A. Poveda Marin, responsible for Phase I-IV Clinical Study, B.Sc. in microbiology from the University of Texas at Austin, USA. He has over 20 years of experience in conducting clinical research & clinical trials. He was responsible for Phase I-IV clinical study projects, including both domestic and global trials.
Cathy Yu. Lawyer, Juris Doctor from the University of Chicago Law School, USA. She has a solid theoretical foundation and has extensive working experience in legal affairs. She has been involved in the drafting of various legal documents and attended relevant conference events on behalf of Congress members. She has an ability of keen insight and deep analysis to all kinds of legal provisions expressed.